Auragens CEO's Award Nod Puts Stem Cell Tourism in the Spotlight

LAS VEGAS, NV – April 23, 2026 – Dr. Dan Briggs, the founder and CEO of regenerative medicine institute Auragens, has been named a finalist for the prestigious Entrepreneur Of The Year® 2026 Pacific Southwest Award by Ernst & Young (EY). The recognition places a significant business community spotlight on a leader in the rapidly growing, yet fiercely debated, field of international stem cell therapy.

Now in its 41st year, the EY program celebrates entrepreneurs who drive market disruption and economic growth. Briggs was selected by an independent panel of judges for his entrepreneurial spirit, purpose, and the remarkable growth of his company. Headquartered in Las Vegas, Auragens operates its primary clinical and research center in Panama City, Panama, a strategic choice that places it at the center of the global medical tourism industry.

“This recognition is meaningful because it reflects something much larger than any one individual, it represents the work of an entire organization committed to raising the standard in regenerative medicine,” Dr. Briggs stated in a press release. He emphasized that the company was built on a philosophy of combining “uncompromising science and an exceptional experience,” a dual focus that has attracted a global clientele.

An Entrepreneurial Ascent in a High-Stakes Field

Dr. Briggs' nomination highlights a classic entrepreneurial narrative of identifying a market need and scaling a business against the odds. With a PhD in public health and degrees from Stanford and Pepperdine, his career has spanned healthcare, energy, and non-profits. At Auragens, he has championed a vision he calls “Healthcare 2.0,” aiming to shift medicine from intervention to regeneration and wellness optimization.

This vision has translated into staggering growth. The company reports year-over-year growth exceeding 10 times the industry average. While specific financials for the private company are not public, the global regenerative medicine market is itself booming, with some projections estimating it will grow from over $35 billion in 2024 to $90 billion by 2030. Auragens’ purported hyper-growth suggests it is successfully capturing a significant share of this expanding market.

Under Briggs’ leadership, the company has accumulated accolades including 'Top Stem Cell Treatment Center' and 'Most Innovative Company to Watch,' building a brand that appeals to high-profile clients, including professional athletes and business leaders from over forty countries.

The Panama Model: Innovation at the Global Frontier

Auragens’ operational structure is central to its business model. While corporate strategy is run from Las Vegas, all patient treatments occur at its “five-star” facility in Panama. This model is a direct response to differing international regulatory landscapes for cellular therapies.

Panama has cultivated a reputation as a hub for regenerative medicine, featuring a regulatory framework that is more permissive than that of the United States. The U.S. Food and Drug Administration (FDA) has strict regulations on the use and manipulation of stem cells, and most mesenchymal stem cell (MSC) therapies, like those offered by Auragens, are not approved for widespread clinical use. In Panama, these treatments are permitted, allowing companies like Auragens to offer advanced protocols, often involving higher cell counts and multiple administrations, that are unavailable in the U.S.

This regulatory difference has fueled a thriving medical tourism industry. Auragens has capitalized on this by creating what it describes as a “luxury, comprehensive, patient experience.” Testimonials featured by the company praise the high-end facilities and attentive care, blending advanced medical intervention with premium hospitality. This approach caters to an international clientele willing to travel and pay significant sums for access to treatments they cannot receive at home.

Navigating the Science and Scrutiny of Stem Cells

At the core of Auragens’ work are mesenchymal stem cells derived from Wharton’s Jelly, the tissue found in the umbilical cord. This sourcing avoids the ethical controversy associated with embryonic stem cells. The company asserts its commitment to safety and quality by highlighting its AABB (Association for the Advancement of Blood & Biotherapies) accreditation and ISO certification for its laboratory—credentials that signify adherence to rigorous international standards for cell processing and quality management.

However, the broader “stem cell tourism” industry in which Auragens operates is not without its critics. Medical and bioethics organizations frequently warn of clinics in less-regulated jurisdictions making unproven claims and exploiting vulnerable patients. The International Society for Stem Cell Research (ISSCR) cautions patients about treatments that have not undergone rigorous, peer-reviewed clinical trials, citing risks of ineffective outcomes or serious harm.

The industry is rife with debate, and patient experiences can vary. While Auragens promotes glowing testimonials, online forums contain a wider spectrum of feedback. One individual who claimed to have undergone treatment expressed mixed feelings online, noting, “The facilities are beautiful and the experience feels like a high-end spa—but that's not why you pay ~$40k.” This sentiment underscores the challenge for patients in distinguishing between a luxury experience and scientifically validated medical efficacy.

Auragens seeks to counter this skepticism by emphasizing its commitment to producing evidence and publishing its findings, aiming to bring what Dr. Briggs calls “trust, transparency and confidence to the industry.”

The EY award nomination for Dr. Briggs serves as a powerful acknowledgment of his business acumen and Auragens' market impact. Regional winners will be announced in June, with the potential to advance to the national competition in November. This recognition from a mainstream business authority places a powerful validation on a company operating on the cutting edge of medicine, simultaneously highlighting the complex intersection of entrepreneurial innovation, patient hope, and the ongoing global debate over the future of regenerative therapy.